Cargando…

Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants

BACKGROUND: The variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) harbor diverse spike (S) protein sequences, which can greatly influence the efficacies of therapeutics. Therefore, it would be of great value to develop neutralizing monoclonal antibodies (mAbs) that can broadly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ko, Shih-Han, Chen, Wan-Yu, Su, Shih-Chieh, Lin, Hsiu-Ting, Ke, Feng-Yi, Liang, Kang-Hao, Hsu, Fu-Fei, Kumari, Monika, Fu, Chi-Yu, Wu, Han-Chung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774083/ https://www.ncbi.nlm.nih.gov/pubmed/36550570 http://dx.doi.org/10.1186/s12929-022-00891-2

Ejemplares similares

Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
por: Hwang, Yu-Chyi, et al.
Publicado: (2022)

Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19
por: Lu, Ruei-Min, et al.
Publicado: (2021)

An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization
por: Hsu, Fu-Fei, et al.
Publicado: (2022)

Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice
por: Lu, Ruei-Min, et al.
Publicado: (2023)

A broadly neutralizing nanobody targeting the highly conserved S2 subunit of sarbecoviruses
por: Wang, Xiaoyun, et al.
Publicado: (2023)

Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain
por: Lai, Guan-Chun, et al.
Publicado: (2022)

Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies
por: Yang, Ming-Chen, et al.
Publicado: (2023)

Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses
por: Peng, Yuan, et al.
Publicado: (2022)

Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern
por: Kumari, Monika, et al.
Publicado: (2023)

Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants
por: Wu, Wan-Ling, et al.
Publicado: (2022)

Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2
por: Zheng, Zhiqiang, et al.
Publicado: (2020)

Development of high affinity broadly reactive aptamers for spike protein of multiple SARS-CoV-2 variants
por: Le, Thao T., et al.
Publicado: (2023)

Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit
por: Cai, Yanxing, et al.
Publicado: (2020)

S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit
por: Nguyen-Contant, Phuong, et al.
Publicado: (2020)

Neutralization of Japanese Encephalitis Virus by heme-induced broadly reactive human monoclonal antibody
por: Gupta, Nimesh, et al.
Publicado: (2015)

A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding
por: Wang, Yingdan, et al.
Publicado: (2022)

SARS-CoV-2 Omicron spike glycoprotein receptor binding domain exhibits super-binder ability with ACE2 but not convalescent monoclonal antibody
por: Omotuyi, Olaposi, et al.
Publicado: (2022)

Ceftazidime exhibits a broad inhibition to the infection of SARS-CoV-2 prototype and Omicron variant in vitro by blocking spike protein-ACE2 interaction
por: Zheng, Yun-zhe, et al.
Publicado: (2023)

Development and Characterization of Broadly Cross-reactive Monoclonal Antibodies Against All Known Ebolavirus Species
por: Hernandez, Humberto, et al.
Publicado: (2015)

A broadly cross-reactive monoclonal antibody against hepatitis E virus capsid antigen
por: Kubickova, Barbara, et al.
Publicado: (2021)

A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
por: Ejemel, Monir, et al.
Publicado: (2020)

A monoclonal antibody with broad specificity for the ligands of insulin B:9-23 reactive T cells prevents spontaneous type 1 diabetes in mice
por: Cepeda, Joseph Ray, et al.
Publicado: (2020)

MCPIP1 ribonuclease exhibits broad-spectrum antiviral effects through viral RNA binding and degradation
por: Lin, Ren-Jye, et al.
Publicado: (2013)

Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing
por: Elshabrawy, Hatem A., et al.
Publicado: (2012)

Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations
por: Tsai, Ming-Shao, et al.
Publicado: (2022)

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
por: Jette, Claudia A., et al.
Publicado: (2021)

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
por: Jette, Claudia A., et al.
Publicado: (2021)

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
por: Jette, Claudia A., et al.
Publicado: (2021)

HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration
por: Lu, Ying, et al.
Publicado: (2023)

Detection of cross-reactive immunoglobulin A against the severe acute respiratory syndrome-coronavirus-2 spike 1 subunit in saliva
por: Tsukinoki, Keiichi, et al.
Publicado: (2021)

A Broadly Cross-Reactive Monoclonal Antibody Against an Epitope on the N-terminus of Meningococcal fHbp
por: Vu, David M., et al.
Publicado: (2012)

Characterization of a Broadly Reactive Anti-CD40 Agonistic Monoclonal Antibody for Potential Use as an Adjuvant
por: Martin, Cameron, et al.
Publicado: (2017)

Murine monoclonal antibodies against RBD of the SARS-CoV-2 spike protein as useful analytical tools for subunit vaccine development and clinical trials
por: Blanco, Omar R., et al.
Publicado: (2022)

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit
por: Hurlburt, Nicholas K., et al.
Publicado: (2022)

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker
por: Chen, Yuning, et al.
Publicado: (2021)

The Effects of Aβ(1-42) Binding to the SARS-CoV-2 Spike Protein S1 Subunit and Angiotensin-Converting Enzyme 2
por: Hsu, John Tsu-An, et al.
Publicado: (2021)

SARS-CoV-2 spike S2-specific neutralizing antibodies
por: Li, Chia-Jung, et al.
Publicado: (2023)

Assessment of adjuvantation strategy of lipid squalene nanoparticles for enhancing the immunogenicity of a SARS-CoV-2 spike subunit protein against COVID-19
por: Ho, Hui-Min, et al.
Publicado: (2021)

Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein
por: Spiga, Ottavia, et al.
Publicado: (2003)

Isomeric triazines exhibit unique profiles of bioorthogonal reactivity
por: Kamber, David N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8v0gj6eaht2cigddob0hj6nepm